CHAPTER 1. METHODOLOGY AND SCOPE
1.1. MARKET SEGMENTATION
1.1.1. MARKET DEFINITIONS
1.2. OBJECTIVES
1.3. RESEARCH METHODOLOGY
1.4. INFORMATION PROCUREMENT
1.4.1. PURCHASED DATABASE
1.4.2. GVR’S INTERNAL DATABASE
1.4.3. SECONDARY SOURCES
1.4.4. PRIMARY RESEARCH
1.5. INFORMATION OR DATA ANALYSIS
1.5.1. DATA ANALYSIS MODELS
1.6. MARKET FORMULATION & VALIDATION
1.7. MODEL DETAILS
1.7.1. COMMODITY FLOW ANALYSIS
1.8. LIST OF SECONDARY SOURCES
1.9. LIST OF ABBREVIATIONS
1.10. LIST OF PRIMARY SOURCES
CHAPTER 2. EXECUTIVE SUMMARY
2.1. MARKET SNAPSHOT
2.2. PRODUCT AND TYPE SNAPSHOT
2.3. APPLICATION AND END USE SNAPSHOT
2.4. TEST TYPE AND COVERAGESNAPSHOT
2.5. COMPETITIVE LANDSCAPE SNAPSHOT
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. MARKET SEGMENTATION AND SCOPE
3.2. MARKET LINEAGE OUTLOOK
3.2.1. PARENT MARKET OUTLOOK
3.2.2. RELATED/ANCILLARY MARKET OUTLOOK
3.3. MARKET DYNAMICS
3.4. MARKET DRIVERS
3.4.1. RISING PREVALENCE OF CANCER
3.4.2. TECHNOLOGICAL ADVANCEMENTS
3.4.3. RISING INITIATIVES UNDERTAKEN BY PUBLIC AND PRIVATE ORGANIZATIONS
3.4.4. EXTENSIVE R&D FOR THE DEVELOPMENT OF NOVEL TESTING SOLUTIONS
3.5. MARKET RESTRAINT ANALYSIS
3.5.1. HIGH COST OF DIAGNOSTIC IMAGING
3.5.2. RADIATION EXPOSURE LIKELY TO LIMIT USAGE OF CT SCANS
3.5.3. RISING ADOPTION OF REFURBISHED DIAGNOSTIC IMAGING SYSTEMS
3.6. BUSINESS ENVIRONMENT ANALYSIS
3.6.1. SWOT ANALYSIS; BY FACTOR (POLITICAL & LEGAL, ECONOMIC AND TECHNOLOGICAL)
3.6.2. PORTER’S FIVE FORCES ANALYSIS
3.6.3. COVID-19 IMPACT ANALYSIS
3.7. MARKET OPPORTUNITY ANALYSIS
3.7.1. ADVENT OF PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
3.8. ARTIFICIAL INTELLIGENCE LANDSCAPE FOR CANCER DIAGNOSTICS
3.8.1. MARKET TRENDS
3.8.2. NEW PRODUCT DEVELOPMENT
3.8.3. LIST OF KEY PLAYERS WITH THEIR OFFERINGS
3.9. COMPARATIVE ANALYSIS OF SOLID VS. LIQUID BIOPSIES
3.10. TRENDS IN BLOOD-BASED DIAGNOSTICS
3.11. CFDNA TEST LANDSCAPE
3.11.1. APPROVED TESTS
3.11.2. CLINICAL TRIALS LANDSCAPE
3.12. NGS TESTS LANDSCAPE
3.13. TRENDS IN EARLY DETECTION
3.13.1. EARLY DETECTION IN ASYMPTOMATIC PATIENTS
3.13.2. SYMPTOMATIC PATIENTS
3.13.3. RECURRENCE DETECTION
3.14. U.S. CANCER RESEARCH GRANTS FUNDING LANDSCAPE
3.14.1. BY CANCER TYPE
3.14.2. BY STATE
3.15. PATENT FILING LANDSCAPE
3.16. QUALITATIVE ANALYSIS OF HOW UPCOMING TECHNOLOGIES FIT INTO PATIENT PATHWAYS
CHAPTER 4. PRODUCT BUSINESS ANALYSIS
4.1. CANCER DIAGNOSTICS MARKET: PRODUCT MOVEMENT ANALYSIS
4.2. INSTRUMENTS
4.2.1. INSTRUMENTS MARKET, 2025 - 2033
4.2.2. PATHOLOGY BASED-INSTRUMENTS
4.2.2.1. SLIDE STAINING SYSTEMS
4.2.2.1.1. SLIDE STAINING SYSTEMS MARKET, 2025 - 2033
4.2.2.2. TISSUE PROCESSING SYSTEMS
4.2.2.2.1. TISSUE PROCESSING SYSTEMS MARKET, 2025 - 2033
4.2.2.3. CELL PROCESSORS
4.2.2.3.1. CELL PROCESSORS SYSTEMS MARKET, 2025 - 2033
4.2.2.4. PCR INSTRUMENTS
4.2.2.4.1. PCR INSTRUMENTS MARKET, 2025 - 2033
4.2.2.5. NGS INSTRUMENTS
4.2.2.5.1. NGS INSTRUMENTS MARKET, 2025 - 2033
4.2.2.6. MICROARRAYS
4.2.2.6.1. MICROARRAYS MARKET, 2025 - 2033
4.2.2.7. OTHER PATHOLOGY-BASED INSTRUMENTS
4.2.2.7.1. OTHER PATHOLOGY-BASED INSTRUMENTS MARKET, 2025 - 2033
4.2.3. IMAGING INSTRUMENTS
4.2.4. OTHERS
4.3. CONSUMABLES
4.3.1. CONSUMABLES MARKET, 2025 - 2033
4.4. SERVICES
4.4.1. SERVICES MARKET, 2025 - 2033
CHAPTER 5. TYPE BUSINESS ANALYSIS
5.1. CANCER DIAGNOSTICS MARKET: TYPE MOVEMENT ANALYSIS
5.2. IVD
5.2.1. IVD MARKET, 2025 - 2033
5.2.2. IVD MARKET, BY TYPE 2025 - 2033
5.2.2.1. DIAGNOSIS
5.2.2.1.1. DIAGNOSIS MARKET, 2025 - 2033
5.2.2.2. EARLY DETECTION
5.2.2.2.1. EARLY DETECTION MARKET, 2025 - 2033
5.2.2.3. THERAPY SELECTION
5.2.2.3.1. THERAPY SELECTION MARKET, 2025 - 2033
5.2.2.4. MONITORING
5.2.2.4.1. MONITORING MARKET, 2025 - 2033
5.2.3. IVD MARKET, BY TECHNOLOGY 2025 - 2033
5.2.3.1. POLYMERASE CHAIN REACTION (PCR)
5.2.3.1.1. POLYMERASE CHAIN REACTION (PCR) MARKET, 2025 - 2033
5.2.3.2. IN SITU HYBRIDIZATION (ISH)
5.2.3.2.1. IN SITU HYBRIDIZATION (ISH) MARKET, 2025 - 2033
5.2.3.3. IMMUNOHISTOCHEMISTRY (IHC)
5.2.3.3.1. IMMUNOHISTOCHEMISTRY (IHC) MARKET, 2025 - 2033
5.2.3.4. NEXT-GENERATION SEQUENCING (NGS)
5.2.3.4.1. NEXT-GENERATION SEQUENCING (NGS) MARKET, 2025 - 2033
5.2.3.5. MICROARRAYS
5.2.3.5.1. MICROARRAYS MARKET, 2025 - 2033
5.2.3.6. FLOW CYTOMETRY
5.2.3.6.1. FLOW CYTOMETRY MARKET, 2025 - 2033
5.2.3.7. IMMUNOASSAYS
5.2.3.7.1. IMMUNOASSAYS MARKET, 2025 - 2033
5.2.3.8. OTHER IVD TESTING TECHNOLOGIES
5.2.3.8.1. OTHER IVD TESTING TECHNOLOGIES MARKET, 2025 - 2033
5.3. LDT
5.3.1. LDT MARKET, 2025 - 2033
5.4. IMAGING
5.4.1. IMAGING MARKET, 2025 - 2033
5.4.2. MAGNETIC RESONANCE IMAGING (MRI)
5.4.2.1. MAGNETIC RESONANCE IMAGING (MRI) MARKET, 2025 - 2033
5.4.3. COMPUTED TOMOGRAPHY (CT)
5.4.3.1. COMPUTED TOMOGRAPHY (CT) MARKET, 2025 - 2033
5.4.4. POSITRON EMISSION TOMOGRAPHY (PET)
5.4.4.1. POSITRON EMISSION TOMOGRAPHY (PET) MARKET, 2025 - 2033
5.4.5. MAMMOGRAPHY
5.4.5.1. MAMMOGRAPHY MARKET, 2025 - 2033
5.4.6. ULTRASOUND
5.4.6.1. ULTRASOUND MARKET, 2025 - 2033
5.4.7. OTHERS
5.4.7.1. OTHERS MARKET, 2025 - 2033
CHAPTER 6. APPLICATION BUSINESS ANALYSIS
6.1. CANCER DIAGNOSTICS MARKET: APPLICATION MOVEMENT ANALYSIS
6.2. BREAST CANCER
6.2.1. BREAST CANCER MARKET, 2025 - 2033
6.3. COLORECTAL CANCER
6.3.1. COLORECTAL CANCER MARKET, 2025 - 2033
6.4. CERVICAL CANCER
6.4.1. CERVICAL CANCER MARKET, 2025 - 2033
6.5. LUNG CANCER
6.5.1. LUNG CANCER MARKET, 2025 - 2033
6.6. PROSTATE CANCER
6.6.1. PROSTATE CANCER MARKET, 2025 - 2033
6.7. SKIN CANCER
6.7.1. SKIN CANCER MARKET, 2025 - 2033
6.8. BLOOD CANCER
6.8.1. BLOOD CANCER MARKET, 2025 - 2033
6.9. KIDNEY CANCER
6.9.1. KIDNEY CANCER MARKET, 2025 - 2033
6.10. LIVER CANCER
6.10.1. LIVER CANCER MARKET, 2025 - 2033
6.11. PANCREATIC CANCER
6.11.1. PANCREATIC CANCER MARKET, 2025 - 2033
6.12. OVARIAN CANCER
6.12.1. OVARIAN CANCER MARKET, 2025 - 2033
6.13. OTHERS
6.13.1. OTHERS MARKET, 2025 - 2033
CHAPTER 7. END USE BUSINESS ANALYSIS
7.1. CANCER DIAGNOSTICS MARKET: END USE MOVEMENT ANALYSIS
7.2. HOSPITALS
7.2.1. HOSPITALS MARKET, 2025 - 2033
7.3. LABORATORIES
7.3.1. LABORATORIES MARKET, 2025 - 2033
7.4. OTHERS
7.4.1. OTHERS CANCER DIAGNOSTICS MARKET, 2025 - 2033
CHAPTER 8. TEST TYPE BUSINESS ANALYSIS
8.1. CANCER DIAGNOSTICS MARKET: TEST TYPE MOVEMENT ANALYSIS
8.2. BIOPSY
8.2.1. BIOPSY MARKET, 2025 - 2033
8.2.2. FINE-NEEDLE ASPIRATION
8.2.2.1. FINE-NEEDLE ASPIRATION MARKET, 2025 - 2033
8.2.3. CORE BIOPSY
8.2.3.1. CORE BIOPSY MARKET, 2025 - 2033
8.2.4. SURGICAL BIOPSY
8.2.4.1. SURGICAL BIOPSY MARKET, 2025 - 2033
8.2.5. SKIN BIOPSY /PUNCH BIOPSY
8.2.5.1. SKIN BIOPSY /PUNCH BIOPSY MARKET, 2025 - 2033
8.2.6. OTHERS
8.2.6.1. OTHERS MARKET, 2025 - 2033
8.3. OTHERS
8.3.1. OTHERS CANCER DIAGNOSTICS MARKET, 2025 - 2033
CHAPTER 9. PRODUCT BUSINESS ANALYSIS
9.1. CANCER DIAGNOSTICS MARKET: PRODUCT MOVEMENT ANALYSIS
9.2. INSTRUMENTS
9.2.1. INSTRUMENTS MARKET, 2025 - 2033
9.3. CONSUMABLES KITS AND REAGENTS
9.3.1. CONSUMABLES KITS AND REAGENTS MARKET, 2025 - 2033
9.4. SOFTWARE AND SERVICES
9.4.1. SOFTWARE AND SERVICES MARKET, 2025 - 2033
CHAPTER 10. COVERAGE BUSINESS ANALYSIS
10.1. CANCER DIAGNOSTICS MARKET: COVERAGE MOVEMENT ANALYSIS
10.2. PUBLIC INSURANCE
10.2.1. PUBLIC INSURANCE MARKET, 2025 - 2033
10.3. PRIVATE INSURANCE
10.3.1. PRIVATE INSURANCE MARKET, 2025 - 2033
CHAPTER 11. REGIONAL BUSINESS ANALYSIS
11.1. CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2024 & 2030
11.2. NORTH AMERICA
11.2.1. NORTH AMERICA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.2.2. U.S.
11.2.2.1. KEY COUNTRY DYNAMICS
11.2.2.2. TARGET DISEASE PREVALENCE
11.2.2.3. COMPETITIVE SCENARIO
11.2.2.4. REGULATORY FRAMEWORK
11.2.2.5. REIMBURSEMENT SCENARIO
11.2.2.6. U.S. CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.2.3. CANADA
11.2.3.1. KEY COUNTRY DYNAMICS
11.2.3.2. TARGET DISEASE PREVALENCE
11.2.3.3. COMPETITIVE SCENARIO
11.2.3.4. REGULATORY FRAMEWORK
11.2.3.5. REIMBURSEMENT SCENARIO
11.2.3.6. CANADA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.3. EUROPE
11.3.1. EUROPE CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.3.2. GERMANY
11.3.2.1. KEY COUNTRY DYNAMICS
11.3.2.2. TARGET DISEASE PREVALENCE
11.3.2.3. COMPETITIVE SCENARIO
11.3.2.4. REGULATORY FRAMEWORK
11.3.2.5. REIMBURSEMENT SCENARIO
11.3.2.6. GERMANY CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.3.3. UK
11.3.3.1. KEY COUNTRY DYNAMICS
11.3.3.2. TARGET DISEASE PREVALENCE
11.3.3.3. COMPETITIVE SCENARIO
11.3.3.4. REGULATORY FRAMEWORK
11.3.3.5. REIMBURSEMENT SCENARIO
11.3.3.6. UK CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.3.4. FRANCE
11.3.4.1. KEY COUNTRY DYNAMICS
11.3.4.2. TARGET DISEASE PREVALENCE
11.3.4.3. COMPETITIVE SCENARIO
11.3.4.4. REGULATORY FRAMEWORK
11.3.4.5. REIMBURSEMENT SCENARIO
11.3.4.6. FRANCE CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.3.5. ITALY
11.3.5.1. KEY COUNTRY DYNAMICS
11.3.5.2. TARGET DISEASE PREVALENCE
11.3.5.3. COMPETITIVE SCENARIO
11.3.5.4. REGULATORY FRAMEWORK
11.3.5.5. REIMBURSEMENT SCENARIO
11.3.5.6. ITALY CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.3.6. SPAIN
11.3.6.1. KEY COUNTRY DYNAMICS
11.3.6.2. TARGET DISEASE PREVALENCE
11.3.6.3. COMPETITIVE SCENARIO
11.3.6.4. REGULATORY FRAMEWORK
11.3.6.5. REIMBURSEMENT SCENARIO
11.3.6.6. SPAIN CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.3.7. DENMARK
11.3.7.1. KEY COUNTRY DYNAMICS
11.3.7.2. TARGET DISEASE PREVALENCE
11.3.7.3. COMPETITIVE SCENARIO
11.3.7.4. REGULATORY FRAMEWORK
11.3.7.5. REIMBURSEMENT SCENARIO
11.3.7.6. DENMARK CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.3.8. SWEDEN
11.3.8.1. KEY COUNTRY DYNAMICS
11.3.8.2. TARGET DISEASE PREVALENCE
11.3.8.3. COMPETITIVE SCENARIO
11.3.8.4. REGULATORY FRAMEWORK
11.3.8.5. REIMBURSEMENT SCENARIO
11.3.8.6. SWEDEN CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.3.9. NORWAY
11.3.9.1. KEY COUNTRY DYNAMICS
11.3.9.2. TARGET DISEASE PREVALENCE
11.3.9.3. COMPETITIVE SCENARIO
11.3.9.4. REGULATORY FRAMEWORK
11.3.9.5. REIMBURSEMENT SCENARIO
11.3.9.6. NORWAY CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.4. ASIA PACIFIC
11.4.1. ASIA PACIFIC CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.4.2. JAPAN
11.4.2.1. KEY COUNTRY DYNAMICS
11.4.2.2. TARGET DISEASE PREVALENCE
11.4.2.3. COMPETITIVE SCENARIO
11.4.2.4. REGULATORY FRAMEWORK
11.4.2.5. REIMBURSEMENT SCENARIO
11.4.2.6. JAPAN CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.4.3. CHINA
11.4.3.1. KEY COUNTRY DYNAMICS
11.4.3.2. TARGET DISEASE PREVALENCE
11.4.3.3. COMPETITIVE SCENARIO
11.4.3.4. REGULATORY FRAMEWORK
11.4.3.5. REIMBURSEMENT SCENARIO
11.4.3.6. CHINA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.4.4. INDIA
11.4.4.1. KEY COUNTRY DYNAMICS
11.4.4.2. TARGET DISEASE PREVALENCE
11.4.4.3. COMPETITIVE SCENARIO
11.4.4.4. REGULATORY FRAMEWORK
11.4.4.5. REIMBURSEMENT SCENARIO
11.4.4.6. INDIA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.4.5. SOUTH KOREA
11.4.5.1. KEY COUNTRY DYNAMICS
11.4.5.2. TARGET DISEASE PREVALENCE
11.4.5.3. COMPETITIVE SCENARIO
11.4.5.4. REGULATORY FRAMEWORK
11.4.5.5. REIMBURSEMENT SCENARIO
11.4.5.6. SOUTH KOREA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.4.6. AUSTRALIA
11.4.6.1. KEY COUNTRY DYNAMICS
11.4.6.2. TARGET DISEASE PREVALENCE
11.4.6.3. COMPETITIVE SCENARIO
11.4.6.4. REGULATORY FRAMEWORK
11.4.6.5. REIMBURSEMENT SCENARIO
11.4.6.6. AUSTRALIA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.4.7. THAILAND
11.4.7.1. KEY COUNTRY DYNAMICS
11.4.7.2. TARGET DISEASE PREVALENCE
11.4.7.3. COMPETITIVE SCENARIO
11.4.7.4. REGULATORY FRAMEWORK
11.4.7.5. REIMBURSEMENT SCENARIO
11.4.7.6. THAILAND CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.5. LATIN AMERICA
11.5.1. LATIN AMERICA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.5.2. BRAZIL
11.5.2.1. KEY COUNTRY DYNAMICS
11.5.2.2. TARGET DISEASE PREVALENCE
11.5.2.3. COMPETITIVE SCENARIO
11.5.2.4. REGULATORY FRAMEWORK
11.5.2.5. REIMBURSEMENT SCENARIO
11.5.2.6. BRAZIL CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.5.3. MEXICO
11.5.3.1. KEY COUNTRY DYNAMICS
11.5.3.2. TARGET DISEASE PREVALENCE
11.5.3.3. COMPETITIVE SCENARIO
11.5.3.4. REGULATORY FRAMEWORK
11.5.3.5. REIMBURSEMENT SCENARIO
11.5.3.6. MEXICO CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.5.4. ARGENTINA
11.5.4.1. KEY COUNTRY DYNAMICS
11.5.4.2. TARGET DISEASE PREVALENCE
11.5.4.3. COMPETITIVE SCENARIO
11.5.4.4. REGULATORY FRAMEWORK
11.5.4.5. REIMBURSEMENT SCENARIO
11.5.4.6. ARGENTINA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.6. MEA
11.6.1. MEA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.6.2. SOUTH AFRICA
11.6.2.1. KEY COUNTRY DYNAMICS
11.6.2.2. TARGET DISEASE PREVALENCE
11.6.2.3. COMPETITIVE SCENARIO
11.6.2.4. REGULATORY FRAMEWORK
11.6.2.5. REIMBURSEMENT SCENARIO
11.6.2.6. SOUTH AFRICA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.6.3. SAUDI ARABIA
11.6.3.1. KEY COUNTRY DYNAMICS
11.6.3.2. TARGET DISEASE PREVALENCE
11.6.3.3. COMPETITIVE SCENARIO
11.6.3.4. REGULATORY FRAMEWORK
11.6.3.5. REIMBURSEMENT SCENARIO
11.6.3.6. SAUDI ARABIA CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.6.4. UAE
11.6.4.1. KEY COUNTRY DYNAMICS
11.6.4.2. TARGET DISEASE PREVALENCE
11.6.4.3. COMPETITIVE SCENARIO
11.6.4.4. REGULATORY FRAMEWORK
11.6.4.5. REIMBURSEMENT SCENARIO
11.6.4.6. UAE CANCER DIAGNOSTICS MARKET, 2025 - 2033
11.6.5. KUWAIT
11.6.5.1. KEY COUNTRY DYNAMICS
11.6.5.2. TARGET DISEASE PREVALENCE
11.6.5.3. COMPETITIVE SCENARIO
11.6.5.4. REGULATORY FRAMEWORK
11.6.5.5. REIMBURSEMENT SCENARIO
11.6.5.6. KUWAIT CANCER DIAGNOSTICS MARKET, 2025 - 2033
CHAPTER 12. COMPETITIVE LANDSCAPE
12.1. COMPANY CATEGORIZATION
12.2. CANCER DIAGNOSTICS MARKET SHARE ANALYSIS, 2024
12.3. COMPANY PROFILES
12.3.1. ILLUMINA, INC.
12.3.1.1. COMPANY OVERVIEW
12.3.1.2. FINANCIAL PERFORMANCE
12.3.1.3. PRODUCT BENCHMARKING
12.3.1.4. STRATEGIC INITIATIVES
12.3.2. BECTON, DICKINSON
12.3.2.1. COMPANY OVERVIEW
12.3.2.2. FINANCIAL PERFORMANCE
12.3.2.3. PRODUCT BENCHMARKING
12.3.2.4. STRATEGIC INITIATIVES
12.3.3. GE HEALTHCARE
12.3.3.1. COMPANY OVERVIEW
12.3.3.2. FINANCIAL PERFORMANCE
12.3.3.3. PRODUCT BENCHMARKING
12.3.3.4. STRATEGIC INITIATIVES
12.3.4. QIAGEN N.V.
12.3.4.1. COMPANY OVERVIEW
12.3.4.2. FINANCIAL PERFORMANCE
12.3.4.3. PRODUCT BENCHMARKING
12.3.4.4. STRATEGIC INITIATIVES
12.3.5. ABBOTT LABORATORIES, INC.
12.3.5.1. COMPANY OVERVIEW
12.3.5.2. FINANCIAL PERFORMANCE
12.3.5.3. PRODUCT BENCHMARKING
12.3.5.4. STRATEGIC INITIATIVES
12.3.6. ROCHE DIAGNOSTICS
12.3.6.1. COMPANY OVERVIEW
12.3.6.2. FINANCIAL PERFORMANCE
12.3.6.3. PRODUCT BENCHMARKING
12.3.6.4. STRATEGIC INITIATIVES
12.3.7. SIEMENS HEALTHCARE
12.3.7.1. COMPANY OVERVIEW
12.3.7.2. FINANCIAL PERFORMANCE
12.3.7.3. PRODUCT BENCHMARKING
12.3.7.4. STRATEGIC INITIATIVES
12.3.8. PHILIPS HEALTHCARE
12.3.8.1. COMPANY OVERVIEW
12.3.8.2. FINANCIAL PERFORMANCE
12.3.8.3. PRODUCT BENCHMARKING
12.3.8.4. STRATEGIC INITIATIVES
12.3.9. R. BARD, INC.
12.3.9.1. COMPANY OVERVIEW
12.3.9.2. FINANCIAL PERFORMANCE
12.3.9.3. PRODUCT BENCHMARKING
12.3.9.4. STRATEGIC INITIATIVES
12.3.10. BIOMÉRIEUX SA
12.3.10.1. COMPANY OVERVIEW
12.3.10.2. FINANCIAL PERFORMANCE
12.3.10.3. PRODUCT BENCHMARKING
12.3.10.4. STRATEGIC INITIATIVES
12.3.11. NEOGENOMICS LABORATORIES, INC.
12.3.11.1. COMPANY OVERVIEW
12.3.11.2. FINANCIAL PERFORMANCE
12.3.11.3. PRODUCT BENCHMARKING
12.3.11.4. STRATEGIC INITIATIVES
12.3.12. VOLPARA SOLUTIONS LIMITED
12.3.12.1. COMPANY OVERVIEW
12.3.12.2. FINANCIAL PERFORMANCE
12.3.12.3. PRODUCT BENCHMARKING
12.3.12.4. STRATEGIC INITIATIVES
12.3.13. HOLOGIC INC.
12.3.13.1. COMPANY OVERVIEW
12.3.13.2. FINANCIAL PERFORMANCE
12.3.13.3. PRODUCT BENCHMARKING
12.3.13.4. STRATEGIC INITIATIVES
12.3.14. CANON MEDICAL SYSTEMS CORPORATION
12.3.14.1. COMPANY OVERVIEW
12.3.14.2. FINANCIAL PERFORMANCE
12.3.14.3. PRODUCT BENCHMARKING
12.3.14.4. STRATEGIC INITIATIVES
12.3.15. PENRAD TECHNOLOGIES INC.
12.3.15.1. COMPANY OVERVIEW
12.3.15.2. FINANCIAL PERFORMANCE
12.3.15.3. PRODUCT BENCHMARKING
12.3.15.4. STRATEGIC INITIATIVES
12.3.16. BIONTECH DIAGNOSTICS GMBH
12.3.16.1. COMPANY OVERVIEW
12.3.16.2. FINANCIAL PERFORMANCE
12.3.16.3. PRODUCT BENCHMARKING
12.3.16.4. STRATEGIC INITIATIVES
12.3.17. BIOGENEX
12.3.17.1. COMPANY OVERVIEW
12.3.17.2. FINANCIAL PERFORMANCE
12.3.17.3. PRODUCT BENCHMARKING
12.3.17.4. STRATEGIC INITIATIVES
12.3.18. OTHERS
12.3.18.1. COMPANY OVERVIEW
12.3.18.2. FINANCIAL PERFORMANCE
12.3.18.3. PRODUCT BENCHMARKING
12.3.18.4. STRATEGIC INITIATIVES
12.5. DISTRIBUTION MODEL ANALYSIS FOR MAJOR PLAYERS
12.6. COMPETITIVE HEAT MAP ANALYSIS FOR U.S. CANCER DIAGNOSTICS MARKET, 2025
12.7. COMPETITIVE HEAT MAP ANALYSIS FOR UK CANCER DIAGNOSTICS MARKET, 2025
12.8. LIST OF CANCERS OF UNKNOWN PRIMARY DIAGNOSTICS COMPANIES
12.9. GUARDANT TEST EVALUATION
CHAPTER 13. CONCLUSION/KEY TAKEWAYS
著作権 ©2022 無断複写・転載を禁じます
